NCT01135433已完成3 期
A Phase 3 Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 168
- 主要终点
- Change from baseline in HbA1c
研究概览
简要总结
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and metformin in patients with diabetes mellitus.
详细描述
This study is to evaluate the efficacy (HbA1c change from baseline) and safety of ASP1941 in combination with metformin in subjects with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control with metformin alone. The effects of ASP1941 are compared with those of placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetic patients receiving with metformin mono-therapy for at least 6 weeks
- •HbA1c value between 7.0 and 9.5%
- •Body Mass Index (BMI) 20.0 - 45.0 kg/m2
排除标准
- •Type 1 diabetes mellitus patients
- •Serum creatinine > upper limit of normal
- •Estimated GFR < 60ml/min/1.73m2
- •Proteinuria (albumin/creatinine ratio > 300mg/g)
- •Dysuria and/or urinary tract infection, genital infection
- •Significant renal, hepatic or cardiovascular diseases
- •Severe gastrointestinal diseases
研究组 & 干预措施
ASP group
Experimental
ASP1941 and metformin
干预措施: ipragliflozin (Drug)
ASP group
Experimental
ASP1941 and metformin
干预措施: metformin (Drug)
Placebo group
Placebo Comparator
placebo and metformin
干预措施: Placebo (Drug)
Placebo group
Placebo Comparator
placebo and metformin
干预措施: metformin (Drug)
结局指标
主要结局
Change from baseline in HbA1c
时间窗: Baseline and for 24 weeks
次要结局
- Change from baseline in fasting plasma glucose(Baseline and for 24 weeks)
- Change from baseline in fasting serum insulin(Baseline and for 24 weeks)
- Safety as reflected by adverse events, routine safety laboratories, vital signs, physical examinations and 12-lead electrocardiograms (ECGs)(for 52 weeks)
研究者
相似试验
已完成
3 期
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01242215Astellas Pharma Inc243
已完成
3 期
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01225081Astellas Pharma Inc152
已完成
3 期
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01242202Astellas Pharma Inc113
已完成
3 期
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01316107Astellas Pharma Inc122
已完成
3 期
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic PatientsType 2 Diabetes MellitusNCT01242228Astellas Pharma Inc106